UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

High grade serous ovarian carcinomas originate in the fallopian tube

Nature communications, 2017-10, Vol.8 (1), p.1093-11, Article 1093

2017

Volltextzugriff (PDF)

Ovarian stimulation with letrozole in nulliparous young women with relapsing early-stage serous borderline ovarian tumors

Gynecologic oncology reports, 2024-12, Vol.56, p.101531, Article 101531

2024

Volltextzugriff (PDF)

Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer

Gynecologic oncology, 2014-03, Vol.132 (3), p.542-550

2014

Volltextzugriff (PDF)

Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response

Critical reviews in oncology/hematology, 2016-05, Vol.101, p.50-59

2016

Volltextzugriff (PDF)

Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study

Swiss medical weekly, 2023-03, Vol.153 (3), p.40055

2023

Volltextzugriff (PDF)

Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer

Clinical cancer research, 2018-01, Vol.24 (2), p.326-333

2018

Volltextzugriff (PDF)

Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer

Seminars in cancer biology, 2021-12, Vol.77, p.127-143

2021

Volltextzugriff (PDF)

Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Scientific reports, 2020-11, Vol.10 (1), p.19248-19248, Article 19248

2020

Volltextzugriff (PDF)

Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin

BMC cancer, 2008-01, Vol.8 (1), p.28-28, Article 28

2008

Volltextzugriff (PDF)

Shallow whole genome re-sequencing to precisely predict benefit from PARP inhibitor

Oncogene, 2023-11, Vol.42 (48), p.3543-3544

2023

Volltextzugriff (PDF)

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Scientific reports, 2020-04, Vol.10 (1), p.7073-7073, Article 7073

2020

Volltextzugriff (PDF)

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review

Annals of translational medicine, 2020-12, Vol.8 (24), p.1712-1712

2020

Volltextzugriff (PDF)

Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis

Gynecologic oncology, 2020-02, Vol.156 (2), p.377-386

2020

Volltextzugriff (PDF)

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

Breast cancer research and treatment, 2019-04, Vol.174 (3), p.775-783

2019

Volltextzugriff (PDF)

Clinical Development of Anti-mitotic Drugs in Cancer

Advances in experimental medicine and biology, 2017, Vol.1002, p.125-152

2017

Volltextzugriff (PDF)

Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature

Familial cancer, 2023-07, Vol.22 (3), p.283-289

2023

Volltextzugriff (PDF)

Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix

Gynecologic oncology reports, 2024-06, Vol.53, p.101394, Article 101394

2024

Volltextzugriff (PDF)

Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms

Gynecologic oncology, 2014-02, Vol.132 (2), p.328-333

2014

Volltextzugriff (PDF)

Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors

The Journal of pathology, 2018-12, Vol.246 (4), p.459-469

2018

Volltextzugriff (PDF)

Carcinome vesiculo-papillaire sur thyroïde linguale

Annales d'oto-laryngologie et de chirurgie cervico-faciale, 2006-09, Vol.123 (4), p.199-202

2006

Volltextzugriff (PDF)

Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors

Oncogene, 2015-01, Vol.34 (3), p.373-383

2015

Volltextzugriff (PDF)

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

Gynecologic oncology reports, 2020-08, Vol.33, p.100600, Article 100600

2020

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(78)
Französisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(44)
Humans
(40)
Oncology
(33)
Female
(30)
Middle Aged
(21)
Adult
(19)
Cancer
(17)
Ovarian Cancer
(17)
Breast Cancer
(14)
Tumors
(14)
Aged
(13)
Life Sciences
(11)
Retrospective Studies
(9)
Brca1 Protein - Genetics
(8)
Brca2 Protein - Genetics
(8)
Breast Neoplasms - Pathology
(8)
Chemotherapy
(8)
Obstetrics & Gynecology
(8)
Antineoplastic Agents - Therapeutic Use
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

High grade serous ovarian carcinomas originate in the fallopian tube

Ovarian stimulation with letrozole in nulliparous young women with relapsing early-stage serous borderline ovarian tumors

Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer

Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response

Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study

Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer

Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer

Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin

Shallow whole genome re-sequencing to precisely predict benefit from PARP inhibitor

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms

Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

Clinical Development of Anti-mitotic Drugs in Cancer

Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature

Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix

Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms

Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors

Carcinome vesiculo-papillaire sur thyroïde linguale

Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

Suchergebnisse filtern